Genomic Medicine
Studying how genomic sequencing can be integrated into clinical care for healthy individuals and families.
Associate Professor of Population Medicine
Associate Director, Precision Medicine Translational Research (PROMoTeR) Center
Harvard Pilgrim Health Care Institute • Harvard Medical School
Welcome! I am an Associate Professor of Population Medicine at the Harvard Pilgrim Health Care Institute and Harvard Medical School, and Associate Director of the Precision Medicine Translational Research Center (PROMoTeR). My research focuses on the clinical, behavioral, and economic impact of genomic medicine, with an emphasis on integrating genomic sequencing into health care in ways that improve patient outcomes and inform health policy.
Come see me present a talk titled, "Ten-year follow-up of a randomized trial of newborn genomic screening: design of the LIVING Study" at the 2026 Annual Meeting of the American Public Health Association! My talk is abstract #596665 at 4:30 on Sunday, November 1.
This website is being updated. Thank you for your patience.
Congratulations and thank you to Madison Hickingbotham, who presented LIVING Study findings at the 2026 ELSICon Meeting as a talk titled, "Reimagining newborn screening: ideal program design envisioned by public health laboratory professionals, clinicians, and researchers." Public health labs are critical to state newborn screening programs and whether/how such programs integrate genomic testing!![]()
I'm delighted to announce that our research team will be collaborating on the newly funded study titled PopScreen, short for Population Genomic Screening in Primary Care. This effort is one of a network of NIH-funded programs to develop and evaluate scalable approaches to offering population-based genetic testing to broad adult populations.
Studying how genomic sequencing can be integrated into clinical care for healthy individuals and families.
Evaluating value, costs, and policy implications of genomic technologies in health care settings.
Examining psychosocial, behavioral, and provider outcomes associated with clinical and consumer genomic testing.